Tome Biosciences is the programmable gene insertion company. Using CRISPR, our technologies allow us to insert any genetic sequence of any size at any location into any genome. We are writing the final chapter in genomic medicines, delivering cures to patients through cell and genome engineering.
Location: United States, Massachusetts, Watertown
Employees: 51-200
Total raised: $213M
Investors 1
| Date | Name | Website |
| 26.03.2022 | ARCH Ventu... | archventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2023 | Series A | $213M | - |
Mentions in press and media 3
| Date | Title | Description |
| 18.12.2023 | Tome Biosciences: Programmable Genomic Integration Company Raises Over $200 Million | Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of ... |
| 13.12.2023 | Tome Biosciences Raises Over $213M in Series A and Series B | Tome Biosciences, Inc., a Watertown, MA-based programmable genomic integration company, raised $213m in Series A and B funding. Backers included Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Part... |
| 12.12.2023 | Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform | - |